今天是:2019-11-21 星期四

黄蓓晖医师:该研究的伦理审批文件未上传,请尽快上传。 调整剂量IRD方案(IRD-lite)治疗复发难治多发性骨髓瘤患者的临床研究
下载XML文档

注册号:

Registration number:

ChiCTR1900026349 

最近更新日期:

Date of Last Refreshed on:

2019-10-01 

注册时间:

Date of Registration:

2019-10-01 

注册号状态:

预注册  

Registration Status:

Prospective registration  

注册题目:

黄蓓晖医师:该研究的伦理审批文件未上传,请尽快上传。 调整剂量IRD方案(IRD-lite)治疗复发难治多发性骨髓瘤患者的临床研究 

Public title:

Modified IRD (IRD-lite) in Relapsed /Refratory Multiple Myeloma 

注册题目简写:

 

English Acronym:

 

研究课题的正式科学名称:

调整剂量IRD方案(IRD-lite)治疗复发难治多发性骨髓瘤患者的临床研究 

Scientific title:

Modified IRD (IRD-lite) in Relapsed /Refratory Multiple Myeloma 

研究课题代号(代码):

Study subject ID:

 

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

 

申请注册联系人:

黄蓓晖 

研究负责人:

李娟 

Applicant:

Beihui Huang 

Study leader:

Juan Li 

申请注册联系人电话:

Applicant telephone:

+86 13570223456 

研究负责人电话:

Study leader's telephone:

+86 13719209240 

申请注册联系人传真 :

Applicant Fax:

 

研究负责人传真:

Study leader's fax:

 

申请注册联系人电子邮件:

Applicant E-mail:

hbh_st@126.com 

研究负责人电子邮件:

Study leader's E-mail:

hbh_st@126.com 

申请单位网址(自愿提供):

Applicant website(voluntary supply):

 

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

 

申请注册联系人通讯地址:

广东省广州市中山二路58号 

研究负责人通讯地址:

广东省广州市中山二路58号 

Applicant address:

58 Second Zhongshan Road, Guangzhou, Guangdong 

Study leader's address:

58 Second Zhongshan Road, Guangzhou, Guangdong 

申请注册联系人邮政编码:

Applicant postcode:

510080 

研究负责人邮政编码:

Study leader's postcode:

510080 

申请人所在单位:

中山大学附属第一医院 

Applicant's institution:

The First Affiliated Hospital, Sun Yat-Sen University 

是否获伦理委员会批准:

是 

Approved by ethic committee:

Yes 

伦理委员会批件文号:

Approved No. of ethic committee:

[2019]340 

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学附属第一医院临床科研和实验动物伦理委员会 

Name of the ethic committee:

ICE for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-Sen University 

伦理委员会批准日期:

Date of approved by ethic committee:

2019-09-16 

伦理委员会联系人:

颜楚荣 

Contact Name of the ethic committee:

Churong Yan 

伦理委员会联系地址:

广东省广州市中山二路58号 

Contact Address of the ethic committee:

58 Second Zhongshan Road, Guangzhou, Guangdong 

伦理委员会联系人电话:

Contact phone of the ethic committee:

 

伦理委员会联系人邮箱:

Contact email of the ethic committee:

 

研究实施负责(组长)单位:

中山大学附属第一医院 

Primary sponsor:

The First Affiliated Hospital, Sun Yat-Sen University 

研究实施负责(组长)单位地址:

广东省广州市中山二路58号 

Primary sponsor's address:

58 Second Zhongshan Road, Guangzhou, Guangdong 

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学附属第一医院

具体地址:

中山二路58号

Institution
hospital:

The First Affiliated Hospital, Sun Yat-sen University

Address:

58 Second Zhongshan Road

经费或物资来源:

无 

Source(s) of funding:

NO 

研究疾病:

多发性骨髓瘤 

Target disease:

multiple myeloma 

研究疾病代码:

 

Target disease code:

 

研究类型:

观察性研究 

Study type:

Observational study 

研究所处阶段:

II期临床试验 

Study phase:

研究目的:

评估IRD-lite方案在复发多发性骨髓瘤患者中的PFS、短期疗效及毒副作用。 

Objectives of Study:

Evaluate progression-free survival,response rate and toxicity for IRD-lite in Relapsed/Refractory Multiple Myeloma. 

药物成份或治疗方案详述:

patients who has received standard anti-myeloma therapy in the past and evaluated as progression or recurrence. 

Description for medicine or protocol of treatment in detail:

 

研究设计:

单臂 

Study design:

Single arm 

纳入标准:

1. 年龄在18岁至75岁之间; 2. 符合2014 年IMWG 多发性骨髓瘤诊断标准的初诊患者; 3. 既往接受过规范的抗骨髓瘤治疗后评价疗效为疾病进展或复发; 4. ECOG行为表现状态为0-3级; 5. 预计生存时间>6个月; 6. 接受治疗14天内符合以下指标:总胆红素≤3倍正常上限,ALT和/或AST≤3倍正常上限; 7. 理解并愿意参加本项临床试验并提供签署的知情同意书; 8. 无怀孕能力或在用药期间及停药90天内同意避孕的患者; 

Inclusion criteria

1. Aged 18-75 years. 2. Relapsed/refractory MM according to the updated IMWG diagnostic criteria 2014 requiring treatment. 3. Patients who has received standard anti-myeloma therapy in the past and evaluated as progression or recurrence. 4. EGCO 0-3. 5. Estimated survival times over 6 months. 6. Meet all of the following blood criteria within 14 days before therapy: a. Total bilirubin <= 3 x upper limit of normal (ULN). b. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) <= 3 x ULN. 7. Meet the pregnancy prevention requirements: not of childbearing potential or agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug. 8. Able to provide written informed consent. 

排除标准:

1. 在最近3个月内参加过其他临床研究; 2. 有任何其它的恶性肿瘤病史; 3. 有严重感染或器质性疾病且疾病未控制的患者; 4. 哺乳期或妊娠期女性。 

Exclusion criteria:

1. Received other clinical trials for multiple myeloma within three months. 2. Prior or concurrent invasive malignancies. 3. Active systemic infection or any other medical or psychiatric condition which, in the opinion of the investigator, contraindicates the participant's participation in this study. 4. Woman in lactation or preganancy. 

研究实施时间:

Study execute time:

From2019-10-01To 2023-09-30 

干预措施:

Interventions:

组别:

1

样本量:

30

Group:

1

Sample size:

干预措施:

IRD-lite

干预措施代码:

Intervention:

IRD-lite

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国 

省(直辖市):

广东 

市(区县):

广州 

Country:

China 

Province:

Guangdong 

City:

Guangzhou 

单位(医院):

中山大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital, Sun Yat-Sen University  

Level of the institution:

Tertiary A 

测量指标:

Outcomes:

指标中文名:

无进展生存

指标类型:

主要指标 

Outcome:

progression free survival

Type:

Primary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

反应率

指标类型:

次要指标 

Outcome:

response rate

Type:

Secondary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

毒副作用

指标类型:

次要指标 

Outcome:

toxicity

Type:

Secondary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁 

说明

Fate of sample:

Destruction after use 

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

not randomized research

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

点击下载

Calculated Results after
the Study Completed(upload file):

download

原始数据公开时间:

The time of sharing IPD:

即时公开/Real time access

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中山大学附属第一医院

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The First Affiliated Hospital, Sun Yat-sen University

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

无/No

注册人:

Name of Registration:

 2019-10-01
返回列表